Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
313 GBX | 0.00% | -5.15% | -11.21% |
Apr. 02 | MaxCyte inks deal with Be Bio; Orcadian firms farmout | AN |
Apr. 02 | MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines | CI |
Financials (USD)
Sales 2024 * | 34.22M | Sales 2025 * | 45.52M | Capitalization | 406M |
---|---|---|---|---|---|
Net income 2024 * | -51M | Net income 2025 * | -45M | EV / Sales 2024 * | 6.8 x |
Net cash position 2024 * | 173M | Net cash position 2025 * | 143M | EV / Sales 2025 * | 5.78 x |
P/E ratio 2024 * |
-7.82
x | P/E ratio 2025 * |
-9.31
x | Employees | 143 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.02% |
Latest transcript on MaxCyte, Inc.
1 week | -5.15% | ||
Current month | -8.61% | ||
1 month | -4.43% | ||
3 months | -24.12% | ||
6 months | +27.76% | ||
Current year | -11.21% |
Managers | Title | Age | Since |
---|---|---|---|
Maher Masoud
CEO | Chief Executive Officer | 49 | - |
Douglas Swirsky
DFI | Director of Finance/CFO | 54 | 23-03-26 |
James Brady
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Balthrop
BRD | Director/Board Member | 67 | 22-11-30 |
Art Mandell
BRD | Director/Board Member | 71 | 06-04-30 |
Will Brooke
BRD | Director/Board Member | 68 | 04-02-29 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.20% | 12 M€ | -.--% | - | |
0.06% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 313 | 0.00% | 458 |
24-04-18 | 313 | -0.63% | 273 |
24-04-17 | 315 | 0.00% | 7,144 |
24-04-16 | 315 | 0.00% | 225 |
24-04-15 | 315 | -4.55% | 7,673 |
Delayed Quote London S.E., April 19, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.21% | 407M | |
+2.64% | 207B | |
+1.80% | 175B | |
+8.59% | 132B | |
+16.47% | 99.1B | |
-3.42% | 60.89B | |
+12.71% | 52.04B | |
-6.61% | 45.48B | |
-4.53% | 38.81B | |
+9.27% | 38.77B |
- Stock Market
- Equities
- MXCT Stock